Lexeo Therapeutics (LXEO) Accumulated Expenses (2022 - 2026)

Lexeo Therapeutics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $8.2 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 49.62% year-over-year to $8.2 million; the TTM figure through Mar 2026 stood at $8.2 million (down 49.62% YoY), while the FY2025 annual figure was $9.3 million, up 125.61% from the prior year.
• Accumulated Expenses came in at $8.2 million for Q1 2026 at Lexeo Therapeutics, down from $9.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $16.2 million in Q1 2025 to a low of $1.8 million in Q3 2023.
• A 5-year average of $7.8 million and a median of $7.3 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 764.43% in 2024 and sank 81.0% in 2025, its largest moves.
• Lexeo Therapeutics' Accumulated Expenses stood at $6.4 million in 2022, then soared by 68.85% to $10.8 million in 2023, then slumped by 62.07% to $4.1 million in 2024, then jumped by 125.61% to $9.3 million in 2025, then declined by 12.05% to $8.2 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $8.2 million, $9.3 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison